X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB NOVARTIS UNICHEM LAB/
NOVARTIS
 
P/E (TTM) x 30.5 364.8 8.4% View Chart
P/BV x 3.2 18.0 17.9% View Chart
Dividend Yield % 0.6 1.6 36.8%  

Financials

 UNICHEM LAB   NOVARTIS
EQUITY SHARE DATA
    UNICHEM LAB
Mar-16
NOVARTIS
Mar-16
UNICHEM LAB/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs334982 34.0%   
Low Rs174556 31.3%   
Sales per share (Unadj.) Rs146.9252.9 58.1%  
Earnings per share (Unadj.) Rs11.962.1 19.1%  
Cash flow per share (Unadj.) Rs16.263.3 25.6%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.81.3 60.6%  
Book value per share (Unadj.) Rs105.1363.6 28.9%  
Shares outstanding (eoy) m90.8431.96 284.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.73.0 56.9%   
Avg P/E ratio x21.412.4 172.6%  
P/CF ratio (eoy) x15.712.2 129.1%  
Price / Book Value ratio x2.42.1 114.2%  
Dividend payout %16.816.1 104.5%   
Avg Mkt Cap Rs m23,07324,580 93.9%   
No. of employees `0005.70.8 754.4%   
Total wages/salary Rs m2,5581,801 142.0%   
Avg. sales/employee Rs Th2,352.510,748.9 21.9%   
Avg. wages/employee Rs Th450.92,395.2 18.8%   
Avg. net profit/employee Rs Th190.42,641.1 7.2%   
INCOME DATA
Net Sales Rs m13,3468,083 165.1%  
Other income Rs m192829 23.1%   
Total revenues Rs m13,5388,913 151.9%   
Gross profit Rs m1,639234 699.8%  
Depreciation Rs m39037 1,062.7%   
Interest Rs m292 1,600.0%   
Profit before tax Rs m1,4121,025 137.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-417 -22.2%   
Extraordinary Inc (Exp) Rs m-351,696 -2.1%   
Tax Rs m293752 38.9%   
Profit after tax Rs m1,0801,986 54.4%  
Gross profit margin %12.32.9 423.9%  
Effective tax rate %20.773.4 28.3%   
Net profit margin %8.124.6 32.9%  
BALANCE SHEET DATA
Current assets Rs m5,97912,678 47.2%   
Current liabilities Rs m2,4322,433 100.0%   
Net working cap to sales %26.6126.7 21.0%  
Current ratio x2.55.2 47.2%  
Inventory Days Days6333 192.9%  
Debtors Days Days6022 268.5%  
Net fixed assets Rs m6,40369 9,252.3%   
Share capital Rs m182160 113.7%   
"Free" reserves Rs m9,29311,460 81.1%   
Net worth Rs m9,54811,621 82.2%   
Long term debt Rs m2300-   
Total assets Rs m12,84314,400 89.2%  
Interest coverage x50.0570.5 8.8%   
Debt to equity ratio x00-  
Sales to assets ratio x1.00.6 185.1%   
Return on assets %8.613.8 62.6%  
Return on equity %11.317.1 66.2%  
Return on capital %14.323.6 60.8%  
Exports to sales %29.20.7 3,923.5%   
Imports to sales %6.318.6 34.1%   
Exports (fob) Rs m3,90060 6,477.7%   
Imports (cif) Rs m8471,503 56.3%   
Fx inflow Rs m4,356186 2,338.4%   
Fx outflow Rs m1,1621,821 63.8%   
Net fx Rs m3,194-1,635 -195.4%   
CASH FLOW
From Operations Rs m1,1192,531 44.2%  
From Investments Rs m-853-8,270 10.3%  
From Financial Activity Rs m-334-386 86.6%  
Net Cashflow Rs m-68-6,125 1.1%  

Share Holding

Indian Promoters % 50.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 15.1 2.0 755.0%  
FIIs % 3.0 1.6 187.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 21.5 147.4%  
Shareholders   20,176 41,647 48.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   SUN PHARMA  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare UNICHEM LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Feb 16, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS